News
BGNE
196.74
+0.24%
0.47
New additions to Roth MKM’s ADR portfolio for September
Seeking Alpha · 1d ago
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 1d ago
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 1d ago
Tracking Baker Brothers Portfolio - Q2 2024 Update
Seeking Alpha · 2d ago
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
TipRanks · 3d ago
Weekly Report: what happened at BGNE last week (0902-0906)?
Weekly Report · 4d ago
Innovent Bio hopes for plus-sized profits from obesity drug
Benzinga · 6d ago
Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?
Barchart · 09/04 02:49
Weekly Report: what happened at BGNE last week (0826-0830)?
Weekly Report · 09/02 09:05
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC
Seeking Alpha · 09/01 07:01
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
NASDAQ · 08/28 13:55
3 US Stocks That Could Be Trading At A Discount
Simply Wall St · 08/28 11:07
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Barchart · 08/28 05:01
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
NASDAQ · 08/26 13:55
Top 2 Health Care Stocks That May Plunge In August
Benzinga · 08/26 11:53
BeiGene stock rises on FDA fast track tag for investigational cancer therapy
Seeking Alpha · 08/26 11:07
BeiGene Says FDA Granted Fast Track Designation To BGB-16673 For Adult Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
Benzinga · 08/26 10:02
Weekly Report: what happened at BGNE last week (0819-0823)?
Weekly Report · 08/26 09:05
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
Benzinga · 08/23 18:10
Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting
Seeking Alpha · 08/23 15:25
More
Webull provides a variety of real-time BGNE stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About BGNE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.